# Ruxolitinib Phosphate in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

> **NCT03041636** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 1 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Untreated Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** Ruxolitinib
- **DRUG:** Ruxolitinib Phosphate

## Key facts

- **NCT ID:** NCT03041636
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-08
- **Primary completion:** 2020-04-29
- **Final completion:** 2020-04-29
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2021-04-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03041636

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03041636, "Ruxolitinib Phosphate in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03041636. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*